OncoMatch/Clinical Trials/NCT04888481

68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors

Is NCT04888481 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies 68Ga-HA-DOTATATE for neuroendocrine tumors.

Phase 2RecruitingUniversity of AlbertaNCT04888481Data as of May 2026

Treatment: 68Ga-HA-DOTATATE — Somatostatin receptor (SSR) imaging is a critical component of clinical care for many patients being investigated for or with confirmed SSR positive tumors. In the past, 111In-octreotide imaging has been used for this purpose but it has been recently supplanted globally by SSR positron emission tomography (PET) imaging due to better image quality and higher diagnostic accuracy. This study will assess the safety and diagnostic effectiveness of 68Ga-HA-DOTATATE produced a the Edmonton Radiopharmaceutical Centre (ERC).

Check if I qualify

Extracted eligibility criteria

Cancer type

Neuroendocrine Tumor

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify